KR20050102080A - 이뇨제 또는 이노제 및 ａｃｅ 억제제의 혼합물에 과민성을가진 개인에서 심장병을 감소하는 방법 및 투여 형태들 - Google Patents

이뇨제 또는 이노제 및 ａｃｅ 억제제의 혼합물에 과민성을가진 개인에서 심장병을 감소하는 방법 및 투여 형태들 Download PDF

Info

Publication number
KR20050102080A
KR20050102080A KR1020057011108A KR20057011108A KR20050102080A KR 20050102080 A KR20050102080 A KR 20050102080A KR 1020057011108 A KR1020057011108 A KR 1020057011108A KR 20057011108 A KR20057011108 A KR 20057011108A KR 20050102080 A KR20050102080 A KR 20050102080A
Authority
KR
South Korea
Prior art keywords
patients
treatment
study
hypertension
antihypertensive
Prior art date
Application number
KR1020057011108A
Other languages
English (en)
Korean (ko)
Inventor
제퍼슨 제이 그레고리
빅토리아 크리스찬
로버트 엠 캘리프
레이몬드 제이 리피키
Original Assignee
킹 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 킹 파마슈티컬즈, 인크. filed Critical 킹 파마슈티컬즈, 인크.
Publication of KR20050102080A publication Critical patent/KR20050102080A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057011108A 2002-12-16 2003-12-16 이뇨제 또는 이노제 및 ａｃｅ 억제제의 혼합물에 과민성을가진 개인에서 심장병을 감소하는 방법 및 투여 형태들 KR20050102080A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43384502P 2002-12-16 2002-12-16
US60/433,845 2002-12-16

Publications (1)

Publication Number Publication Date
KR20050102080A true KR20050102080A (ko) 2005-10-25

Family

ID=32681973

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057011108A KR20050102080A (ko) 2002-12-16 2003-12-16 이뇨제 또는 이노제 및 ａｃｅ 억제제의 혼합물에 과민성을가진 개인에서 심장병을 감소하는 방법 및 투여 형태들

Country Status (10)

Country Link
EP (1) EP1589965A1 (fr)
JP (1) JP2006511567A (fr)
KR (1) KR20050102080A (fr)
CN (1) CN1731996A (fr)
AU (1) AU2003303208A1 (fr)
BR (1) BR0317326A (fr)
CA (1) CA2508269A1 (fr)
IL (1) IL169148A0 (fr)
MX (1) MXPA05006399A (fr)
WO (1) WO2004056360A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536975A1 (fr) 2003-08-28 2005-03-17 Nitromed, Inc. Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
EP1734931A2 (fr) 2004-03-24 2006-12-27 Actavis Group Formulations de ramipril
WO2006091716A2 (fr) 2005-02-24 2006-08-31 Nitromed, Inc. Compositions et composes diuretiques renforçateurs d'oxyde nitrique, et leurs procedes d'utilisation
US9769354B2 (en) 2005-03-24 2017-09-19 Kofax, Inc. Systems and methods of processing scanned data
US9576272B2 (en) 2009-02-10 2017-02-21 Kofax, Inc. Systems, methods and computer program products for determining document validity
US9767354B2 (en) 2009-02-10 2017-09-19 Kofax, Inc. Global geographic information retrieval, validation, and normalization
US10146795B2 (en) 2012-01-12 2018-12-04 Kofax, Inc. Systems and methods for mobile image capture and processing
US9165188B2 (en) 2012-01-12 2015-10-20 Kofax, Inc. Systems and methods for mobile image capture and processing
US9208536B2 (en) 2013-09-27 2015-12-08 Kofax, Inc. Systems and methods for three dimensional geometric reconstruction of captured image data
US9355312B2 (en) 2013-03-13 2016-05-31 Kofax, Inc. Systems and methods for classifying objects in digital images captured using mobile devices
CN105283884A (zh) 2013-03-13 2016-01-27 柯法克斯公司 对移动设备捕获的数字图像中的对象进行分类
US20140316841A1 (en) 2013-04-23 2014-10-23 Kofax, Inc. Location-based workflows and services
EP2992481A4 (fr) 2013-05-03 2017-02-22 Kofax, Inc. Systèmes et procédés pour détecter et classifier des objets dans une vidéo capturée à l'aide de dispositifs mobiles
US9386235B2 (en) 2013-11-15 2016-07-05 Kofax, Inc. Systems and methods for generating composite images of long documents using mobile video data
US9760788B2 (en) 2014-10-30 2017-09-12 Kofax, Inc. Mobile document detection and orientation based on reference object characteristics
US10242285B2 (en) 2015-07-20 2019-03-26 Kofax, Inc. Iterative recognition-guided thresholding and data extraction
US9779296B1 (en) 2016-04-01 2017-10-03 Kofax, Inc. Content-based detection and three dimensional geometric reconstruction of objects in image and video data
US11062176B2 (en) 2017-11-30 2021-07-13 Kofax, Inc. Object detection and image cropping using a multi-detector approach
CN109524075A (zh) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 基于数据处理的药品费用超标风险控制方法及装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055904A (en) * 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MXPA05006399A (es) 2006-01-27
WO2004056360A1 (fr) 2004-07-08
JP2006511567A (ja) 2006-04-06
CN1731996A (zh) 2006-02-08
IL169148A0 (en) 2007-07-04
EP1589965A1 (fr) 2005-11-02
CA2508269A1 (fr) 2004-07-08
AU2003303208A1 (en) 2004-07-14
BR0317326A (pt) 2005-11-16

Similar Documents

Publication Publication Date Title
Writing Committee et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee
KR20050102080A (ko) 이뇨제 또는 이노제 및 ａｃｅ 억제제의 혼합물에 과민성을가진 개인에서 심장병을 감소하는 방법 및 투여 형태들
Patel et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a report of the American College of Cardiology appropriate use criteria task force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons
Leung et al. Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension
Ambrosius et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)
National Collaborating Centre for Chronic Conditions (Great Britain) Hypertension: management in adults in primary care: pharmacological update
Cushman et al. Original Papers. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT)
Furberg et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Selnes et al. Do management strategies for coronary artery disease influence 6-year cognitive outcomes?
Swedberg et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005) The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Kitzman et al. Importance of heart failure with preserved systolic function in patients≥ 65 years of age
Maron et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities
Joint National Committee on Detection et al. The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure
Chaves et al. Subclinical cardiovascular disease in older adults: insights from the Cardiovascular Health Study
Piller et al. Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone
Schoen et al. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease
Ripley et al. Key articles and guidelines in the management of hypertension: 2015 update
Piterman et al. Chronic heart failure: optimising care in general practice
Levine Managing multiple cardiovascular risk factors: state of the science
Ardehali et al. A practical approach to cardiovascular medicine
Piller et al. Current Controlled Trials in Cardiovascular Medicine
Ng et al. Consensus statement on ischaemic stroke care in Hong Kong
Joss et al. Vascular disease and survival in patients with type 2 diabetes and nephropathy
Probstfield et al. Systolic hypertension the elderly program (SHEP): the first demonstration that lowering systolic hypertension reduced total stroke and all coronary heart disease
Manafe Characterization of severe and complicated hypertension in Mozambican adults

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid